Research by DealForma

Decades of context backed by data from the DealForma database

Run your analyses better, in less time, with the newest database built for biopharma, medtech, and diagnostics.

Learn MoreSchedule Your Demo

21,135

Licensing Deals

4,145

M&A

5,766

Other Deals

21,479

Funding Rounds

34,717

Company Profiles

26,805

Drug Sales Figures

All of this by stage, disease indication, modality, target

Biopharma IPO Watch: Therapeutics & Platforms

Biopharma IPO Watch: Therapeutics & Platforms

Biopharma IPO activity was still quiet through the second quarter 2023 with 3 companies going public on global exchanges for a total of $800 million. This follows 3 IPOs in the first quarter at $400 million. Among these IPOs, Laekna raised approximately $101 million...

M&A In Biopharma Therapeutics & Platforms – Q2 2023

M&A In Biopharma Therapeutics & Platforms – Q2 2023

Biopharma M&A activity in Q2 2023 picked up as the number of therapeutics and discovery platform company acquisitions tracked higher. The second quarter of 2023 saw 27 M&A deals for a total upfront of $27.4 billion or $28.1 billion when counting contingent...

Neurology M&A Snapshot Through Q2 2023

Neurology M&A Snapshot Through Q2 2023

We are looking at mergers and acquisitions in the neurology space through June 2023. As with the broader biopharma sector, neurology deal flow has been down since 2020. The year started with a decent number of billion-plus acquisitions in other biopharma therapeutic...

R&D Partnerships by TA – Autoimmune

R&D Partnerships by TA – Autoimmune

So far, 2023 has witnessed a mixed landscape for R&D partnerships in the autoimmune sector. While there were notable activities and collaborations, there was a decline in the number of deals and the overall value compared to previous years. This suggests a...

R&D Partnerships – Medtech – Q1 2023

R&D Partnerships – Medtech – Q1 2023

Medtech R&D partnerships play a significant role in driving innovation and advancements in healthcare. Medtech's various focus areas, such as medical devices, digital health solutions, and wearable technologies, saw active collaboration and investment, but deal...

Introducing: DealForma plus Tableau

Introducing: DealForma plus Tableau

We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...

Venture & IPO – Medtech – Q1 2023 

Venture & IPO – Medtech – Q1 2023 

The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...

M&A – Biopharma Therapeutics And Platforms – Q1 2023

M&A – Biopharma Therapeutics And Platforms – Q1 2023

Biopharma M&A started to in the first quarter of 2023 after a slow 2022. Major deals included Moderna's acquisition of OriCiro Genomics for $85 million, expanding Moderna's manufacturing capabilities for mRNA vaccines. Pfizer's blockbuster $43 billion acquisition...

Venture & IPO – Medtech

Venture & IPO – Medtech

Venture & IPO - Medtech As the demand for innovative medical technologies continues to grow, many entrepreneurs and investors are exploring ways to finance the development and commercialization of new MedTech products. Two popular options for raising capital in...

M&A – Medtech

M&A – Medtech

M&A – Medtech Medical technology, or MedTech, is a multidisciplinary field that combines technology and medical interventions. It encompasses various technologies, devices, services, products, and solutions that employ medical technology to improve patient care...

R&D Partnerships – Medtech

R&D Partnerships – Medtech

R&D PARTNERSHIPS – MEDTECH As we enter the first quarter of 2023, there is a persistent rise in R&D spending despite the mounting pressure to cut costs, reduce budgets and enhance profit margins. The life sciences sector anticipated an R&D expenditure of...

M&A – Biopharma Therapeutics And Platforms

M&A – Biopharma Therapeutics And Platforms

M&A – Biopharma Therapeutics And Platforms Mergers and Acquisitions are related concepts that refer to consolidating two or more companies into a single entity. In a merger, two or more companies come together to form a new company, while in an acquisition, one...

Biopharma Therapeutics & Platforms Paradigm

Biopharma Therapeutics & Platforms Paradigm

Biopharma Therapeutics & Platforms Paradigm  Biopharmaceutical companies that develop new therapies and health technologies are essential for advancing drug development in its early stages. That's why US biotech firms are highly sought after by private equity...